The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 07, 2023

Filed:

Jun. 01, 2018
Applicant:

Wave Life Sciences Ltd., Singapore, SG;

Inventors:

Chandra Vargeese, Schwenksville, PA (US);

Naoki Iwamoto, Brighton, MA (US);

David Charles Donnell Butler, Medford, MA (US);

Subramanian Marappan, Acton, MA (US);

Genliang Lu, Winchester, MA (US);

Jason Jingxin Zhang, Walpole, MA (US);

Vinod Vathipadiekal, Stoneham, MA (US);

Luciano Henrique Apponi, Chelsea, MA (US);

Hanna Maria Wisniewska, Providence, RI (US);

Xiayun Cheng, Old Saybrook, CT (US);

Young Jin Cho, Belmont, MA (US);

Assignee:

WAVE LIFE SCIENCES LTD., Singapore, SG;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); A61K 47/54 (2017.01); A61K 47/55 (2017.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C12N 15/113 (2013.01); A61K 45/06 (2013.01); A61K 47/54 (2017.08); A61K 47/545 (2017.08); A61K 47/548 (2017.08); A61K 47/549 (2017.08); A61K 47/55 (2017.08); C12N 2310/14 (2013.01); C12N 2310/315 (2013.01); C12N 2310/32 (2013.01); C12N 2310/33 (2013.01); C12N 2310/352 (2013.01);
Abstract

Among other things, the present disclosure provides designed PNPLA3 oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide improved single-stranded RNA interference and/or RNase H-mediated knockdown. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or N patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, stability, delivery, etc. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions, for example, in RNA interference and/or RNase H-mediated knockdown.


Find Patent Forward Citations

Loading…